The Val34Leu polymorphism in the A subunit of blood coagulation factor XIII (FXIII-A) is located in the activation peptide, just three amino acids upstream of the thrombin cleavage site. The Val™Leu replacement accelerates the rate of the proteolytic activation of FXIII and it seems to provide protection against myocardial infarction. Methods available for the assessment of the FXIII-A Val34Leu polymorphism are rather time-consuming, laborious and not easily applicable for large-scale studies. In this study a new method based on real-time PCR with fluorescence resonance energy transfer (FRET) detection and melting curve analysis was developed. The rapid, simple method was adapted to the widely used real-time PCR instrument, LightCycler (Roche Diagnostics). The results showed 100% coincidence with those obtained by the traditional PCR-restriction fragment length polymorphism (RFLP) assay and fluorescent DNA sequencing. Using this method, an allele frequency of 24.2% was obtained (ns113), which well agrees with the allele frequency obtained by PCR-RFLP on a different group of the same ethnic Hungarian population (25.9%).
Blood coagulation factor XIII (FXIII) is a zymogen of tetrameric structure (A 2 B 2 ); it consists of two potentially active A subunits (FXIII-A) and two carrier/protective B subunits (FXIII-B). FXIII is converted into an . Thrombin cleaves off an activation peptide of 37 amino acid residues from the N-terminus of FXIII-A, then in the presence of Ca 2q FXIII-B dissociates and FXIII-A assumes an enzymatically active configuration. FXIIIa catalyzes the formation of glutaminyl-lysyl bonds between fibrin chains and covalently cross-links a 2 -plasmin inhibitor to fibrin. In this way FXIIIa mechanically stabilizes the fibrin clot and increases its resistance to fibrinolysis wfor reviews, see (1) (2) (3) x. FXIII-A is a rather polymorphic protein; five common polymorphisms resulting in amino acid replacement have been described (3) . One of these polymorphisms, a G™T substitution in exon 2 resulting in Val™Leu replacement at position 34 (4) (GenBank accession no. M21986), has attracted a lot of interest in the last couple of years. The frequency of the Leu34 allele among Caucasians is around 25%, it is much lower in blacks and Asian Indians and extremely rare in the Japanese population. The site of the polymorphism is just three amino acids upstream of the thrombin cleavage site and it has been shown that the cleavage of the Leu34 variant, and consequently the activation of Leu34 FXIII, occurs significantly faster than that of the wild-type factor (5-7). In the first studies a protective effect of the Leu34 allele against myocardial infarction (8) and venous thrombosis (9) was reported. In follow-up studies both confirmatory and contradictory results were demonstrated wfor a review, see (3)x and further large-scale studies seem to be required for clarifying the conditions under which the Leu34 allele exerts its protective effect.
In the epidemiological studies carried out so far, polymerase chain reaction (PCR) combined with single-stranded conformation polymorphism (SSCP) (8, 10) or restriction fragment length polymorphism (RFLP) (5, 11) detection, allele-specific PCR (12) or solid phase mini-sequencing (13) were used to distinguish among different Val34Leu FXIII-A genotypes. These methods are rather time-consuming, laborious and not easily applicable for large-scale studies. Here, we present an alternative approach based on realtime PCR with fluorescence resonance energy transfer (FRET) detection and melting curve analysis. This rapid, simple method was adapted to the widely used real-time PCR instrument, LightCycler (Roche Diagnostics, Mannheim, Germany).
DNA was isolated from citrated whole blood of 113 unrelated subjects w68 wild-type (V/V), 36 heterozy- gote (V/L), 9 homozygote (L/L)x using the MagNA Pure LC Instrument (Roche Diagnostics). Primers and probes were synthesized by TIB MOLBIOL (Berlin, Germany). The nucleotide compositions of primers and probes are shown in Table 1 . The detection probe (sensor) labeled with fluorescein at the 39 end covers the polymorphic site. A C™A mismatch was introduced in the sensor to decrease the melting temperature for both alleles. The adjacent anchor probe was 59 labeled with LC Red640 dye and the 39 end was phosphorylated to prevent probe elongation by Taq polymerase. The gap between the two probes is a single nucleotide. If the probes lie adjacent to each other on a DNA strand, fluorescence resonance energy transfer occurs and the fluorescence of LC Red640 is detected by the fluorimeter component of LightCycler.
PCR at a 0.18C/s ramping rate. The fluorescent signal of LC Red640 was monitored continuously during the temperature ramp and the results were transformed to derivative melting curves. Melting peak analysis easily discriminated the three different FXIII-A Val34Leu genotypes: melting temperature (T m ) for the wild-type (Val/Val) was at 56.48C, while T m for the homozygote mutant (Leu/Leu) was at 47.58C; heterozygotes demonstrated both peaks (Figure 1) . One hundred and thirteen individual DNA preparations from a sample pool were tested by the method described above and by PCR-RFLP according to Balogh et al. (5) . The results were in 100% concordance. The frequency of the Leu34 allele was 24.2% (95% CI: 16.3-32.1%), which agrees well with the allele frequency obtained by PCR-RFLP on a different group of the same ethnic Hungarian population (25.9%; 95% CI: 22.3-29.5%) (5), and with the data reported for other Caucasian populations (14) . Fifty randomly selected DNA samples (26 wild-type, 19 heterozygous and 5 homozygous for the FXIII-A Val34Leu polymorphism) were also evaluated by fluorescent DNA sequencing using the BigDye Terminator Reaction kit on an ABI 310 Genetic Analyzer (Applied Biosystems; Weiterstadt, Germany); again 100% concordance was observed. To test the reproducibility of the assay, DNA samples of all three genotypes were retested on at least 20 different occasions. All results were consistent. Since the introduction of the assay, 500 patients' samples have been tested for the Val34Leu polymorphism in our laboratory, and in all cases a clear discrimination among the different FXIII-A Val34Leu genotypes has been observed.
Most recently, two real-time PCR methods, apyrasemediated allele-specific primer extension (15) and 59 nuclease assay (16) , were also adapted for genotyping the FXIII-A Val34Leu polymorphism. The results obtained by the assays were compared to those obtained by DNA sequencing on a relatively small number (17 and 20, respectively) of samples. Both methods seem to represent a promising alternative to earlier assays. However, as discrimination among different genotypes by these methods is based on quantitative measures, a comparison to reference methods on a larger number of samples is required to confirm their specificity. The real-time PCR method presented in this study uses FRET detection and differentiates among genotypes on the basis of a clear difference in the T m of wild-type and mutant allele. With LightCycler the amplification of the target DNA and determination of the genotype are performed in the same closed capillary, limiting the risk of error and contamination considerably. The LightCycler software provides a large amount of information from a single run. The assay is specific and reproducible, and the total analysis of 31 samples in the LightCycler takes less than 30 min. Its specificity has been confirmed by comparison with the most frequently used PCR-RFLP method and with DNA sequencing on a large number of samples.
